Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W M Stadler

Showing results (1-10 of 70) with videos related to

Pageof 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2001
Clinical trial designs for cytostatic agentsM J Ratain, W M Stadler
World Journal of Urology|May 26, 2001
Treatment of metastatic urothelial cancer in the post-MVAC eraE E Cohen, W M Stadler
Investigational New Drugs|June 1, 2000
Development of target-based antineoplastic agentsW M Stadler, M J Ratain
Seminars in Oncology|February 1, 1995
Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinomaW M Stadler, N J Vogelzang
Urological Research|January 1, 1996
The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genesW M Stadler, O I Olopade
Actas Urologicas Espanolas|September 12, 1998
[New chemotherapy regimens for advanced bladder cancer]S O Fagbemi, W M Stadler
Seminars in Urologic Oncology|March 21, 1998
New chemotherapy regimens for advanced bladder cancerS O Fagbemi, W M Stadler
The New England Journal of Medicine|September 28, 1998
Cytokine therapy in metastatic renal cancerW M Stadler, N J Vogelzang
Urology|February 5, 1999
Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancerN J Vogelzang, W M Stadler
Lancet (London, England)|December 16, 1998
Kidney cancerN J Vogelzang, W M Stadler
Pageof 7

Showing results (1-10 of 70) with videos related to

Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2001
Clinical trial designs for cytostatic agentsM J Ratain, W M Stadler
World Journal of Urology|May 26, 2001
Treatment of metastatic urothelial cancer in the post-MVAC eraE E Cohen, W M Stadler
Investigational New Drugs|June 1, 2000
Development of target-based antineoplastic agentsW M Stadler, M J Ratain
Seminars in Oncology|February 1, 1995
Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinomaW M Stadler, N J Vogelzang
Urological Research|January 1, 1996
The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genesW M Stadler, O I Olopade
Actas Urologicas Espanolas|September 12, 1998
[New chemotherapy regimens for advanced bladder cancer]S O Fagbemi, W M Stadler
Seminars in Urologic Oncology|March 21, 1998
New chemotherapy regimens for advanced bladder cancerS O Fagbemi, W M Stadler
The New England Journal of Medicine|September 28, 1998
Cytokine therapy in metastatic renal cancerW M Stadler, N J Vogelzang
Urology|February 5, 1999
Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancerN J Vogelzang, W M Stadler
Lancet (London, England)|December 16, 1998
Kidney cancerN J Vogelzang, W M Stadler
Pageof 7